CytomX Therapeutics Inc (CTMX)
4.43
-0.07
(-1.56%)
USD |
NASDAQ |
May 03, 16:00
4.69
+0.26
(+5.87%)
After-Hours: 20:00
CytomX Therapeutics Cash from Financing (TTM): 30.23M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 30.23M |
September 30, 2023 | 30.18M |
June 30, 2023 | 0.507M |
March 31, 2023 | 0.641M |
December 31, 2022 | 0.648M |
September 30, 2022 | 1.141M |
June 30, 2022 | 1.245M |
March 31, 2022 | 1.485M |
December 31, 2021 | 110.21M |
September 30, 2021 | 122.55M |
June 30, 2021 | 122.61M |
March 31, 2021 | 123.47M |
December 31, 2020 | 16.89M |
September 30, 2020 | 4.273M |
June 30, 2020 | 4.169M |
March 31, 2020 | 3.319M |
December 31, 2019 | 1.627M |
Date | Value |
---|---|
September 30, 2019 | 1.95M |
June 30, 2019 | 137.46M |
March 31, 2019 | 137.49M |
December 31, 2018 | 139.62M |
September 30, 2018 | 159.98M |
June 30, 2018 | 25.56M |
March 31, 2018 | 25.51M |
December 31, 2017 | 23.80M |
September 30, 2017 | 3.218M |
June 30, 2017 | 2.309M |
March 31, 2017 | 1.851M |
December 31, 2016 | 0.996M |
September 30, 2016 | 83.14M |
June 30, 2016 | 79.71M |
March 31, 2016 | 152.60M |
December 31, 2015 | 153.40M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.507M
Minimum
Jun 2023
137.46M
Maximum
Jun 2019
37.61M
Average
4.169M
Median
Jun 2020
Cash from Financing (TTM) Benchmarks
Ocular Therapeutix Inc | 169.83M |
Bristol-Myers Squibb Co | 8.278B |
ACADIA Pharmaceuticals Inc | 25.13M |
Cytokinetics Inc | 221.32M |
Calidi Biotherapeutics Inc | -- |